This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Breast Cancer Drug Market

Increasing Clinical Trials & Research Programs for New Cancer Drugs Development to Accelerate the Growth of the Breast Cancer Drug Market

Breast Cancer Drug Market By Drug, Distribution Channel & Region - Forecast 2022-2032

Breast Cancer Drug Market Snapshot (2022-2032)

[300 Pages Report] The global breast cancer drug market size is expected to be valued at US$ 10,637.42 Million in 2022. The increasing prevalence of the disease along with evolving novel therapies are some of the key factors likely to drive the market. Early detection of breast cancer is a key to effective management of the disease. The overall demand for Breast Cancer Drugs is projected to grow at a CAGR of 1.1% between 2022 and 2032, totaling around 11,750.33 Million by 2032.

Data Points

Key Statistics

Breast Cancer Drug Market Value 2022

US$ 10,637.42 Million

Breast Cancer Drug Market Projected Value (2032)

US$ 11,750.33 Million

Breast Cancer Drug Market CAGR (2022-2032)

1.1%

Breast cancer is the most common cancer in women worldwide. From the recent reports on cancer, 1.7 million cases of breast cancer have been recorded in a year. Women living in developed countries such as U.S, U.K, and Australia have a higher risk than in developing countries.

Many factors are responsible for developing breast cancer, factors including lifestyle, age, heredity, and also genetic mutations (abnormal changes). Scientists are working on finding how gene variations are affecting breast cancer and studying new methods for imaging methods to evaluate abnormalities at early stages.

Newer drug valuation is expected to be upward as it is difficult to treat advanced breast cancers. WHO has a global action plan on non-communicable diseases which is endorsed by many countries, which is a part to reduce the growing cases and address women’s cancer.

Over the past few decades, recent advancements and new drug developments have fuelled the breast cancer drug market. In Oct 2021, FDA approved a new drug called abemaciclib - brand name Verzenio for one type of breast cancer. This drug is approved for patients with HR+, HER2-early breast cancer, which makes up 70% of all breast cancers. The drug was already approved for advanced, or metastatic, breast cancer.

Customize this Report

Let us know your requirement to get
100% FREE customization

Breast Cancer Drug Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)

The global demand for Breast Cancer drugs is projected to increase at a CAGR of 1.1% during the forecast period between 2022 and 2032, reaching a total of US$ 11,750.33 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 1.3%.

As per the recent analysis by the American Cancer Society, in U.S., 266,120 new cases were diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. Thereby, the rising occurrence of cancer cases has burgeoned the demand for Breast Cancer Drugs in recent years.

Over the coming years, the soaring emphasis on the development of more effective treatment procedures and advanced drugs is projected to foster the breast cancer drug market.

Which Drivers underpin Breast Cancer Drug Industry Expansion?

The breast cancer drug market is scaling up and the research towards improved chemotherapy drugs and targeted therapies are the major concerns of all medical centers throughout the world. According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2021, breast cancer ranked as the fifth leading cause of death in women; accounting for 627,000 deaths every year.

Several governments and non-profit organizations are working incessantly and organizing programs to increase awareness and provide financial aid to patients diagnosed with breast cancer. For instance, the sister study is a study taken by an organization named the National Institute of Environmental Health Sciences to help women in early diagnosis by considering all the possible factors that affect breast cancer.

New generation treatments and bio-similar versions, Physical inactivity, environmental factors, lifestyle, and hormonal changes during aging pump in the breast cancer drug market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors are limiting the Growth of the Breast Cancer Drug Market?

According to the recently published report by Future Market Insights, the breast cancer drug market is estimated to progress in the future but the stringent rules and regulations, prolonged therapies degrading the health, dearth of accessible medical attention, and healthcare literacy are some aspects that may restrain the market expansion throughout the projection period.

Despite the positive outlook, side effects associated with breast cancer drugs as well as their expensive nature may impede the remuneration scope of the industry during the analysis timeframe.

Region-wise Insights

Will North America Hold a Significant Position in the Global Breast Cancer Drug Market?

In terms of geographic divisions, North America is expected to account for a 52.1% share in the breast cancer drug market in 2022. According to Future Market Insights analysis, the region is estimated to witness significant growth over the forecast period. This market growth is attributed to the increasing number of cases of breast cancer and the lifestyle followed by the women. United and Canada are the prominent shareholders in the regional revenue generation, backed by their robust healthcare infrastructure and high investments in clinical trials.

Additionally, supportive reimbursement policies are likely to positively impact the growth trajectory of the market in the forthcoming years. Moreover, to minimize the pervasiveness of the disease, U.S. President Joe Biden, in 2022, relaunched a program dubbed ‘Moonshot’ to accelerate cancer research, which was first introduced in 2017. The program raised funding of USD 1.8 million in the last 7 years and aims to reduce fatality rates of cancer by a staggering 50% over the next 25 years.

Innovative and progressive treatment procedures like cancer vaccinations are currently being researched in congruence with chemotherapy and immunotherapy as it has been detected that cancer vaccinations have a greater success ratio in killing tumor cells. Some of these vaccinations may be customizable, while others cover a broader spectrum.

How Will Growth of the European Breast Cancer Drug Market unfold?

Based on Future Market Insight’s recent analysis, Europe is expected to account for nearly 26.7% share of the breast cancer drug market in 2022. European nations like France, Germany, and Italy are anticipated to hold vital opportunities and generate the highest revenue share in terms of the breast cancer drugs market. There is a robust plan as Patient Support Programs and campaigns are organized in various countries to spread awareness about breast cancers and early diagnosis and treatment.

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. Approvals of new treatment procedures and soaring investments in R&D by prominent players have fuelled the revenue generation of the European market.

How is Asia Pacific bolstering the Demand for Breast Cancer Drugs?

According to Future Market Insights, Asia Pacific is one of the most significant regions based on the development of the Breast Cancer Drug market and is estimated to witness impressive growth throughout the forecast period. Rapid growth in global demand for drugs has compelled prominent drug manufacturers to set up facilities for manufacturing and R&D in this region.

Initiatives commenced by several organizations to create awareness, educate people, and raise funds for the disease are projected to propel regional growth. For instance, Wacoal Corp. runs the Pink Ribbon Fitting Campaign and donates funds to the Japan Society of Breast Health, J. POSH, and Japan Cancer Society (Smile Fund) on behalf of customers.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

By type, Which Breast Cancer Drug Category will remain Prominent?

The global breast cancer drug market is bifurcated into the drug class, distribution channel, and regions. Breast cancer is the most commonly diagnosed cancer in women worldwide and also is one of the leading causes of death. Based on the drug type segment, the highest growing segment in the treatment of breast cancer is the HER2-positive subtype, and the drug market is showing no sign of slowing down in the future.

The increasing occurrence of HER2-positive breast cancer is the foremost aspect attributed to the growth of this segment. According to a recently published article by F. Hoffman La Roche Ltd, it was assessed that nearly one in five women diagnosed with breast tumors would have HER2-positive cancer. Furthermore, rapidly growing demand from emerging markets such as the Asia Pacific and Latin America is expected to further drive the growth during the forecast period.

CDK 4/6 inhibitor is anticipated to be the fastest growing segment throughout the forecast period. These drugs are likely to improve the survival rate in patients with metastatic breast cancer. Moreover, the commercialization of novel drugs, such as Kisqali by Novartis AG and Verzenio by Eli Lilly and Company is expected to propel the growth of the segment in the forthcoming years.

The Start-Up Ecosystem: How key Players are Opening Frontiers for Future Growth?

  • Founded in 2014, ScreenPoint is a provider of AI-based medical image analysis systems. The company's flagship product, Transpara is based on the automated analysis of digital mammograms and breast tomosynthesis data for the early detection of breast cancer. Transpara enables decision support for soft tissue lesions, CAD, and exam selection for pre-screening. The company is based out of the Netherlands and has collected total funding worth US$ 33 million.
  • Launched in 2014, iSono Health is a developer of a wearable device for early breast cancer detection. The company has developed an automated, portable, and wearable ultrasound imaging platform by using 3D ultrasound technology along with the machine learning algorithm that enables users to scan and capture images of the breast and further share them with the radiologist for analysis and report generation. The company is headquartered in San Fransisco, United States, and received overall funding of 120k Billion from Y Combinator, Plug and Play Tech Center, Gershon Capital, and 5 Other Investors.

Competitive Landscape: What are the Leading Players in the Breast Cancer Drug Market Up to?

  • In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.
  • In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 1.1% from 2022-2032

Market Value in 2022

US$ 10,637.42 Million

Market Value in 2032

US$ 11,750.33 Million

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Drug Class
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • AstraZeneca
  • Novartis International AG
  • Achieve Life Science
  • Bristol-Myers Squibb
  • Eisai Co. Ltd
  • AbbVie
  • Eli Lilly & Company
  • Celgene Corporation
  • Merck & Co.
  • Amgen Plc.
  • Celldex Therapeutics
  • Biocon Genzyme Corporation

Key Segments Covered in the Breast Cancer Drug Industry Analysis

Breast Cancer Drug Market by Drug Class:

  • SERM (Selective Estrogen-Receptor Modulators)-based Breast Cancer Treatment
  • Aromatase Inhibitors-based Breast Cancer Treatment
  • Biologic Response Modifiers-based Breast Cancer Treatment
  • Other Hormonal Therapies-based Breast Cancer Treatment

Breast Cancer Drug Market by Distribution Channel:

  • Breast Cancer Drugs Sales via Hospital Pharmacies
  • Breast Cancer Drugs via Pharmacies
  • Breast Cancer Drugs via Drug Stores

Breast Cancer Drug Market by Region:

  • North America Breast Cancer Drug Market
  • Latin America Breast Cancer Drug Market
  • Europe Breast Cancer Drug Market
  • Asia Pacific Breast Cancer Drug Market
  • Middle East & Africa Breast Cancer Drug Market

Frequently Asked Questions

As of 2022, the breast cancer drug market is slated to reach a valuation of US$ 10,637.42 Million

From 2022-2032, sales of breast cancer drugs are expected to grow at a 1.1% CAGR

By 2032, Future Market Insights expects the Breast Cancer Drug market to reach US$ 11,750.33 Million

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Breast Cancer Drug Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        5.3.1. SERMs (Selective Estrogen-Receptor Modulators)

        5.3.2. Aromatase Inhibitors

        5.3.3. Biologic Response Modifiers

        5.3.4. Other Hormonal Therapies

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

6. Global Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        6.3.1. Hospital Pharmacies

        6.3.2. Pharmacies

        6.3.3. Drug Stores

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2016-2021

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

7. Global Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. US

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. Asia Pacific Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Rest of Asia Pacific

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. MEA Breast Cancer Drug Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Key Countries Breast Cancer Drug Market Analysis

    13.1. US

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2021

            13.1.2.1. By Drug Class

            13.1.2.2. By Distribution Channel

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2021

            13.2.2.1. By Drug Class

            13.2.2.2. By Distribution Channel

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2021

            13.3.2.1. By Drug Class

            13.3.2.2. By Distribution Channel

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2021

            13.4.2.1. By Drug Class

            13.4.2.2. By Distribution Channel

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2021

            13.5.2.1. By Drug Class

            13.5.2.2. By Distribution Channel

    13.6. U.K.

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2021

            13.6.2.1. By Drug Class

            13.6.2.2. By Distribution Channel

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2021

            13.7.2.1. By Drug Class

            13.7.2.2. By Distribution Channel

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2021

            13.8.2.1. By Drug Class

            13.8.2.2. By Distribution Channel

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2021

            13.9.2.1. By Drug Class

            13.9.2.2. By Distribution Channel

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2021

            13.10.2.1. By Drug Class

            13.10.2.2. By Distribution Channel

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2021

            13.11.2.1. By Drug Class

            13.11.2.2. By Distribution Channel

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2021

            13.12.2.1. By Drug Class

            13.12.2.2. By Distribution Channel

    13.13. GCC Countries

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2021

            13.13.2.1. By Drug Class

            13.13.2.2. By Distribution Channel

    13.14. South Africa

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2021

            13.14.2.1. By Drug Class

            13.14.2.2. By Distribution Channel

    13.15. Israel

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2021

            13.15.2.1. By Drug Class

            13.15.2.2. By Distribution Channel

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. F. Hoffmann-La Roche Ltd

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Pfizer Inc.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. AstraZeneca

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Novartis International AG

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Achieve Life Science

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Bristol-Myers Squibb

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Eisai

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. AbbVie

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Eli Lilly & Company

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Celgene Corporation

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

        15.1.11. Merck & Co

            15.1.11.1. Overview

            15.1.11.2. Product Portfolio

            15.1.11.3. Profitability by Market Segments

            15.1.11.4. Sales Footprint

            15.1.11.5. Strategy Overview

                15.1.11.5.1. Marketing Strategy

        15.1.12. Amgen

            15.1.12.1. Overview

            15.1.12.2. Product Portfolio

            15.1.12.3. Profitability by Market Segments

            15.1.12.4. Sales Footprint

            15.1.12.5. Strategy Overview

                15.1.12.5.1. Marketing Strategy

        15.1.13. Celldex Therapeutics

            15.1.13.1. Overview

            15.1.13.2. Product Portfolio

            15.1.13.3. Profitability by Market Segments

            15.1.13.4. Sales Footprint

            15.1.13.5. Strategy Overview

                15.1.13.5.1. Marketing Strategy

        15.1.14. Biocon Genzyme Corporation

            15.1.14.1. Overview

            15.1.14.2. Product Portfolio

            15.1.14.3. Profitability by Market Segments

            15.1.14.4. Sales Footprint

            15.1.14.5. Strategy Overview

                15.1.14.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Breast Cancer Drug Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 2: Global Breast Cancer Drug Market Value (US$ Mn) Forecast by Drug Class, 2016-2032

Table 3: Global Breast Cancer Drug Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 4: North America Breast Cancer Drug Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 5: North America Breast Cancer Drug Market Value (US$ Mn) Forecast by Drug Class, 2016-2032

Table 6: North America Breast Cancer Drug Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 7: Latin America Breast Cancer Drug Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 8: Latin America Breast Cancer Drug Market Value (US$ Mn) Forecast by Drug Class, 2016-2032

Table 9: Latin America Breast Cancer Drug Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 10: Europe Breast Cancer Drug Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 11: Europe Breast Cancer Drug Market Value (US$ Mn) Forecast by Drug Class, 2016-2032

Table 12: Europe Breast Cancer Drug Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 13: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) Forecast by Drug Class, 2016-2032

Table 15: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Table 16: MEA Breast Cancer Drug Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 17: MEA Breast Cancer Drug Market Value (US$ Mn) Forecast by Drug Class, 2016-2032

Table 18: MEA Breast Cancer Drug Market Value (US$ Mn) Forecast by Distribution Channel, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Breast Cancer Drug Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 2: Global Breast Cancer Drug Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 3: Global Breast Cancer Drug Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global Breast Cancer Drug Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 5: Global Breast Cancer Drug Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 6: Global Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global Breast Cancer Drug Market Value (US$ Mn) Analysis by Drug Class, 2016-2032

Figure 8: Global Breast Cancer Drug Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 9: Global Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 10: Global Breast Cancer Drug Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 11: Global Breast Cancer Drug Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 12: Global Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 13: Global Breast Cancer Drug Market Attractiveness by Drug Class, 2022-2032

Figure 14: Global Breast Cancer Drug Market Attractiveness by Distribution Channel, 2022-2032

Figure 15: Global Breast Cancer Drug Market Attractiveness by Region, 2022-2032

Figure 16: North America Breast Cancer Drug Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 17: North America Breast Cancer Drug Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 18: North America Breast Cancer Drug Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Breast Cancer Drug Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 20: North America Breast Cancer Drug Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Breast Cancer Drug Market Value (US$ Mn) Analysis by Drug Class, 2016-2032

Figure 23: North America Breast Cancer Drug Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 24: North America Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 25: North America Breast Cancer Drug Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 26: North America Breast Cancer Drug Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 27: North America Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 28: North America Breast Cancer Drug Market Attractiveness by Drug Class, 2022-2032

Figure 29: North America Breast Cancer Drug Market Attractiveness by Distribution Channel, 2022-2032

Figure 30: North America Breast Cancer Drug Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Breast Cancer Drug Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 32: Latin America Breast Cancer Drug Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 33: Latin America Breast Cancer Drug Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Breast Cancer Drug Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 35: Latin America Breast Cancer Drug Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Breast Cancer Drug Market Value (US$ Mn) Analysis by Drug Class, 2016-2032

Figure 38: Latin America Breast Cancer Drug Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 39: Latin America Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 40: Latin America Breast Cancer Drug Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 41: Latin America Breast Cancer Drug Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 42: Latin America Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 43: Latin America Breast Cancer Drug Market Attractiveness by Drug Class, 2022-2032

Figure 44: Latin America Breast Cancer Drug Market Attractiveness by Distribution Channel, 2022-2032

Figure 45: Latin America Breast Cancer Drug Market Attractiveness by Country, 2022-2032

Figure 46: Europe Breast Cancer Drug Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 47: Europe Breast Cancer Drug Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 48: Europe Breast Cancer Drug Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Breast Cancer Drug Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 50: Europe Breast Cancer Drug Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Breast Cancer Drug Market Value (US$ Mn) Analysis by Drug Class, 2016-2032

Figure 53: Europe Breast Cancer Drug Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 54: Europe Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 55: Europe Breast Cancer Drug Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 56: Europe Breast Cancer Drug Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 57: Europe Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 58: Europe Breast Cancer Drug Market Attractiveness by Drug Class, 2022-2032

Figure 59: Europe Breast Cancer Drug Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: Europe Breast Cancer Drug Market Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 62: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 63: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) by Country, 2022-2032

Figure 64: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 65: Asia Pacific Breast Cancer Drug Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) Analysis by Drug Class, 2016-2032

Figure 68: Asia Pacific Breast Cancer Drug Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 69: Asia Pacific Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 70: Asia Pacific Breast Cancer Drug Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 71: Asia Pacific Breast Cancer Drug Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 72: Asia Pacific Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 73: Asia Pacific Breast Cancer Drug Market Attractiveness by Drug Class, 2022-2032

Figure 74: Asia Pacific Breast Cancer Drug Market Attractiveness by Distribution Channel, 2022-2032

Figure 75: Asia Pacific Breast Cancer Drug Market Attractiveness by Country, 2022-2032

Figure 76: MEA Breast Cancer Drug Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 77: MEA Breast Cancer Drug Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 78: MEA Breast Cancer Drug Market Value (US$ Mn) by Country, 2022-2032

Figure 79: MEA Breast Cancer Drug Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 80: MEA Breast Cancer Drug Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA Breast Cancer Drug Market Value (US$ Mn) Analysis by Drug Class, 2016-2032

Figure 83: MEA Breast Cancer Drug Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 84: MEA Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 85: MEA Breast Cancer Drug Market Value (US$ Mn) Analysis by Distribution Channel, 2016-2032

Figure 86: MEA Breast Cancer Drug Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 87: MEA Breast Cancer Drug Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 88: MEA Breast Cancer Drug Market Attractiveness by Drug Class, 2022-2032

Figure 89: MEA Breast Cancer Drug Market Attractiveness by Distribution Channel, 2022-2032

Figure 90: MEA Breast Cancer Drug Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Breast Biopsy Device Market

Published : May 2016

Healthcare

Breast Biopsy Market

Published : April 2016

Healthcare

Digital Breast Tomosynthesis (DBT) Equipment Market

Published : June 2016

Healthcare

Automated Breast Ultrasound Systems Market

Published : May 2021

Google translate

Breast Cancer Drug Market